|
1
|
Japanese Gastric Cancer Association:
Japanese Classification of Gastric Carcinoma. 3rd English edition.
Gastric Cancer. 14:101–112. 2011.
|
|
2
|
Shiraishi N, Inomata M, Osawa N, Yasuda K,
Adachi Y and Kitano S: Early and late recurrence after gastrectomy
for gastric carcinoma. Univariate and multivariate analyses.
Cancer. 89:255–261. 2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nakajima T: Gastric cancer treatment
guidelines in Japan. Gastric Cancer. 5:1–5. 2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Santoro E, Garofalo A, Scutari FA, Carlini
M, Zanarini T and Santoro E: Multicenter retrospective study of
3,024 patients operated on for stomach cancer in Italy.
Epidemiology, surgical treatment and survival. Ann Gastroenterol
Hepatol (Paris). 27:167–171. 1991.(In French). PubMed/NCBI
|
|
5
|
Park JM, Song KY, O JH, Kim WC, Choi MG
and Park CH: Bone recurrence after curative resection of gastric
cancer. Gastric Cancer. 16:362–369. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shimada H, Okazumi S, Koyama M and
Murakami K: Japanese gastric cancer association task force for
research promotion: Clinical utility of
18F-fluoro-2-deoxyglucose positron emission tomography
in gastric cancer. A systematic review of the literature. Gastric
Cancer. 14:13–21. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2014 (Ver.4). Gastric
Cancer. 20:1–19. 2017.
|
|
8
|
Yoshikawa K and Kitaoka H: Bone metastasis
of gastric cancer. Jpn J Surg. 13:173–176. 1983.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Choi CW, Lee DS, Chung JK, Lee MC, Kim NK,
Choi KW and Koh CS: Evaluation of bone metastasis by Tc-99m MDP
imaging in patients with stomach cancer. Clin Nucl Med. 20:310–314.
1995.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mori W, Adachi Y, Okabe H and Oota K: An
analysis of 755 autopsied cases of malignant tumors. A statistical
study of their metastasis. Gan No Rinsho. 9:351–374. 1963.(In
Japanese).
|
|
11
|
Kobayashi M, Okabayashi T, Sano T and
Araki K: Metastatic bone cancer as a recurrence of early gastric
cancer-characteristics and possible mechanisms. World J
Gastroenterol. 11:5587–5591. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gurzu S, Jung I and Kadar Z: Aberrant
metastatic behavior and particular features of early gastric
cancer. APMIS. 123:999–1006. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dassen AE, Lips DJ, Hoekstra CJ, Pruijt
JFM and Bosscha K: FDG-PET has no definite role in preoperative
imaging in gastric cancer. Eur J Surg Oncol. 35:449–455.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kawamura T, Kusakabe T, Sugino T, Watanabe
K, Fukuda T, Nashimoto A, Honma K and Suzuki T: Expression of
glucose transporter-1 in human gastric carcinoma: Association with
tumor aggressiveness, metastasis, and patient survival. Cancer.
92:634–641. 2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yamada A, Oguchi K, Fukushima M, Imai Y
and Kadoya M: Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose
positron emission tomography in gastric carcinoma: Relation to
histological subtypes, depth of tumor invasion, and glucose
transporter-1 expression. Ann Nucl Med. 20:597–604. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Alakus H, Batur M, Schmidt M, Drebber U,
Baldus SE, Vallböhmer D, Prenzel KL, Metzger R, Bollschweiler E,
Hölscher AH and Mönig S: Variable 18F-fluorodeoxyglucose uptake in
gastric cancer is associated with different levels of GLUT-1
expression. Nucl Med Commun. 31:532–538. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yoshioka T, Yamaguchi K, Kubota K,
Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H and
Kanamaru R: Evaluation of 18F-FDG PET in patients with advanced,
metastatic, or recurrent gastric cancer. J Nucl Med. 44:690–699.
2003.PubMed/NCBI
|
|
18
|
Ma DW, Kim JH, Jeon TJ, Lee YC, Yun M,
Youn YH, Park H and Lee SI: 18F-fluorodeoxyglucose
positron emission tomography-computed tomography for the evaluation
of bone metastasis in patients with gastric cancer. Dig Liver Dis.
45:769–775. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kawanaka Y, Kitajima K, Fukushima K, Mouri
M, Doi H, Oshima T, Niwa H, Kaibe N, Sasako M, Tomita T, et al:
Added value of pretreatment (18)F-FDG PET/CT for staging of
advanced gastric cancer: Comparison with contrast-enhanced MDCT.
Eur J Radiol. 85:989–995. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kang SH, Kim JI, Moon HS, Kang HM, Kim SH,
Seong JK, Lee BS, Jeong HY, Song KS, Noh SM, et al: Overt bone
marrow metastasis from early gastric cancer. Endoscopy. 40:E34–E35.
2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hironaka SI, Boku N, Ohtsu A, Nagashima F,
Sano Y, Muto M, Fujii T, Tajiri H and Yoshida S: Sequential
methotrexate and 5-fluorouracil therapy for gastric cancer patients
with bone metastasis. Gastric Cancer. 3:19–23. 2000.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sasaki Y, Nishina T, Yasui H, Goto M, Muro
K, Tsuji A, Koizumi W, Toh Y, Hara T and Miyata Y: Phase II trial
of nanoparticle albumin-bound paclitaxel as second-line
chemotherapy for unresectable or recurrent gastric cancer. Cancer
Sci. 105:812–817. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shitara K, Takashima A, Fujitani K, Koeda
K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K,
et al: Nab-paclitaxel versus solvent-based paclitaxel in patients
with previously treated advanced gastric cancer (ABSOLUTE): An
open-label, randomised, non-inferiority, phase 3 trial. Lancet
Gastroenterol Hepatol. 2:277–287. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Woo Y, Fujisaki S, Takashina M, Tomita R,
Sakurai K and Takayama T: A case of metastases to the bone, skin,
and ovary from gastric cancer occurring more than eight years after
distal gastrectomy. Gan To Kagaku Ryoho. 44:1571–1573. 2017.(In
Japanese). PubMed/NCBI
|
|
27
|
Takishita C, Yajima K, Iwasaki Y, Ohashi
M, Iwanaga T and Oohinata R: A case of early gastric cancer with
multiple synchronous bone metastases treated complete response with
S-1+CDDP. Gan To Kagaku Ryoho. 41:2611–2614. 2014.(In Japanese).
PubMed/NCBI
|
|
28
|
Choi YJ, Kim DH, Han HS, Han JH, Son SM,
Kim DS and Yun HY: Long-term survival after gastrectomy and
metastasectomy for gastric cancer with synchronous bone metastasis.
World J Gastroenterol. 24:150–156. 2018.PubMed/NCBI View Article : Google Scholar
|
